Article
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
International journal of colorectal disease - 1 Feb 2011
Formica Vincenzo, Palmirotta Raffaele, Del Monte Girolamo, Savonarola Annalisa, Ludovici Giorgia, De Marchis Maria Laura, Grenga Italia, Schirru Michele, Guadagni Fiorella, Roselli Mario
Abstract excerpt
PURPOSE: The aim of this study is to evaluate the influence of germline vascular endothelial growth factor (VEGF) gene polymorphisms (VGPs) on the efficacy of the anti-VEGF antibody bevacizumab (Bev) in metastatic colorectal cancer (MCRC) patients. METHODS: Forty MCRC patients eligible for a first-line therapy were enrolled in this prospective trial and treated with FOLinate/Fluorouracil/Irinotecan...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.